Lucid Diagnostics Inc.

NASDAQ:LUCD

Medical - Devices

Healthcare
$0.41 +3.80%

+$0.04 today

Market cap
$79.38M
Beta
1.08
P/E (TTM)
-2.3
EPS (TTM)
-$0.44
52W Low $0.90High $1.63

Volume 2.70M

Average 0.84M

LUCD Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Lucid Diagnostics Inc.NASDAQ: LUCD

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin widens to -1107.4%

Net margin was -1107.4% in Q1 FY2026, up 2142.4 pp from a year earlier. On a trailing-twelve-month basis it was -876.7%, up 604.8 pp year over year. Over 3 fiscal years it widened by 13666.8 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 1 analysts of -479.1% for the fiscal year ending Dec 2026, up from -1232.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-1107.4%-25.9 pp QoQ
Last fiscal yearDec 2025
-1232.7%-185.1 pp YoY
LTMMar 2026
-876.7%+604.8 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2142.4 pp-376.5 pp-2518.8 pp
1 year-185.1 pp+753.6 pp+938.7 pp
3 years+13666.8 pp+1184.4 pp-12482.4 pp
5 years+1219.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1232.7%
Year-over-year change
-185.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How LUCD compares with its peers on the latest reported figures

  • LUCD's LTM Mar 2026 net margin of -876.7% is the 6th highest of the 10 companies compared; the peer median is -468.7%.
  • Its year-over-year change of +604.8 pp is the highest of 9, against a peer median of -11.2 pp.
  • Over three fiscal years its change of +13666.8 pp compares with a peer median of +20.2 pp.
LUCD Competitors Peer median
Net Margin for LUCD and competitors
Company Period LTM level YoY 3-year change
APYXApyx Medical CorporationLTM Mar 2026-16.4% +26.0 pp+30.9 pp
OWLTOwlet, Inc.LTM Mar 2026-43.0% -27.9 pp+77.1 pp
RCELAVITA Medical, Inc.LTM Mar 2026-62.7% +16.9 pp+9.6 pp
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026-145.8% +5.4 pp+214.6 pp
SEERSeer, Inc.LTM Mar 2026-468.7% +97.4 pp+176.5 pp
LUCDLucid Diagnostics Inc.LTM Mar 2026-876.7% +604.8 pp+13666.8 pp
IRDOpus Genetics, Inc.LTM Mar 2026-892.4% -462.9 pp-394.2 pp
SCLXScilex Holding CompanyLTM Mar 2026-1239.4% -1092.4 pp-1124.4 pp
AVRAnteris Technologies Global Corp.LTM Mar 2026-5148.8% -1866.9 pp-3966.4 pp
STSSSkyAI, Inc.LTM Mar 2026-93391.3% ——
Peer median (excluding LUCD) -468.7%-11.2 pp+20.2 pp

Competitors are the stored peer set for LUCD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue500K377K2.43M4.35M4.71M
Cost of Revenue585K3.61M8.48M8.27M7.54M
Gross Profit(85K)(3.24M)(6.05M)(3.92M)(2.84M)
Gross Margin-17.0%-858.6%-249.2%-90.2%-60.3%
Research & Development9.3M11.47M7.25M5.99M5.68B
Selling, General & Admin18.04M39.82M35.66M36.62B41.58B
Operating Expenses27.33M52.93M42.43M42.13M46.8M
Depreciation & Amortization4K1.94M2.5M1.17M872K
EBITDA(27.42M)(54.23M)(49.75M)(44.34M)(57.12M)
EBITDA Margin-5483.0%-14383.8%-2049.1%-1020.2%-1213.7%
Operating Income(27.42M)(56.17M)(48.48M)(46.05M)(49.64M)
Operating Margin-5483.8%-14899.5%-1996.8%-1059.6%-1054.8%
Interest Income088K424K322K386K
Interest Expense659K8K416K26K22K
Other Income / Expenses(659K)0(4.18M)523K(8.37M)
Income Before Tax(28.08M)(56.17M)(52.67M)(45.53M)(58.01M)
Pre-Tax Margin-5615.6%-14899.5%-2169.1%-1047.6%-1232.7%
Income Tax Expense00000
Net Income(28.08M)(56.17M)(52.67M)(45.53M)(58.01M)
Net Margin-5615.6%-14899.5%-2169.1%-1047.6%-1232.7%
EPS (Basic)(0.78)(1.55)(1.26)(1.05)(0.69)
EPS (Diluted)(0.78)(1.55)(1.26)(1.05)(0.69)
Weighted Avg Shares36.06M36.17M41.76M50.52M101.95M
Weighted Avg Shares (Diluted)36.06M36.17M41.76M50.52M101.95M

Lucid Diagnostics Inc.

NASDAQ:LUCD

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.